Global Imfinzi Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Imfinzi Market Insights, Forecast to 2034
IMFINZI® (durvalumab) is an immunotherapy used to treat patients with urothelial carcinoma, a type of bladder cancer
Global Imfinzi market is expected to reach to US$ 3202 million in 2024, with a positive growth of %, compared with US$ 2784 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Imfinzi industry is evaluated to reach US$ 5734.7 million in 2029. The CAGR will be 10.2% during 2024 to 2029.
The PD-1 and PD-L1 Inhibitor market is driven by the increasing demand for advanced immunotherapy options in oncology. PD-1 and PD-L1 inhibitors are revolutionary treatments that block specific proteins, enhancing the immune system's ability to recognize and attack cancer cells. The growing prevalence of various cancers, coupled with the need for targeted therapies that offer improved efficacy and fewer side effects compared to traditional treatments, contributes to market growth. Additionally, the expanding list of approved indications for these inhibitors, such as melanoma, lung cancer, and more, further propels adoption. However, challenges include managing potential immune-related adverse events and identifying patients who are most likely to respond to these treatments. Navigating the complex landscape of combination therapies and addressing access and affordability barriers for a broader patient population are ongoing concerns. The market's success relies on continuous research to optimize treatment regimens and identify biomarkers for patient selection, comprehensive patient education about the potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and research institutions to advance cancer treatment while addressing the evolving challenges associated with PD-1 and PD-L1 inhibitor therapy.
Report Covers
This report presents an overview of global Imfinzi market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Imfinzi market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
AstraZeneca
Segment by Type
2.4ml
10ml
Retail Pharmacy
Hospital Pharmacy
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Imfinzi plant distribution, commercial date of Imfinzi, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Imfinzi introduction, etc. Imfinzi Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Imfinzi
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Imfinzi market is expected to reach to US$ 3202 million in 2024, with a positive growth of %, compared with US$ 2784 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Imfinzi industry is evaluated to reach US$ 5734.7 million in 2029. The CAGR will be 10.2% during 2024 to 2029.
The PD-1 and PD-L1 Inhibitor market is driven by the increasing demand for advanced immunotherapy options in oncology. PD-1 and PD-L1 inhibitors are revolutionary treatments that block specific proteins, enhancing the immune system's ability to recognize and attack cancer cells. The growing prevalence of various cancers, coupled with the need for targeted therapies that offer improved efficacy and fewer side effects compared to traditional treatments, contributes to market growth. Additionally, the expanding list of approved indications for these inhibitors, such as melanoma, lung cancer, and more, further propels adoption. However, challenges include managing potential immune-related adverse events and identifying patients who are most likely to respond to these treatments. Navigating the complex landscape of combination therapies and addressing access and affordability barriers for a broader patient population are ongoing concerns. The market's success relies on continuous research to optimize treatment regimens and identify biomarkers for patient selection, comprehensive patient education about the potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and research institutions to advance cancer treatment while addressing the evolving challenges associated with PD-1 and PD-L1 inhibitor therapy.
Report Covers
This report presents an overview of global Imfinzi market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Imfinzi market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AstraZeneca
Segment by Type
2.4ml
10ml
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Imfinzi plant distribution, commercial date of Imfinzi, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Imfinzi introduction, etc. Imfinzi Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Imfinzi
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices